Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Clin Genitourin Cancer. 2012 Sep 25;10(4):225–231. doi: 10.1016/j.clgc.2012.08.002

Table 3.

Difference in Progression-free Survival in Patients Who Develop Hypothyroidism

Group of Patients No.
Patients		 Median
Progression-Free
Survival
(95% CI), mo		 P Value
Develop hypothyroidism while on treatment with sunitinib or sorafenib 21 20 (11–25) .02
Remain euthyroid while on treatment with sunitinib or sorafenib 35 6 (4–10)
History of hypothyroidism, develop worsening thyroid dysfunction 10 29 (4–48) .05
History of hypothyroidism, no change in thyroid function 7 7 (3–17)